New hope for Tough-to-Treat multiple myeloma: CM336 enters phase 3 trial

NCT ID NCT07181239

Not yet recruiting Disease control Sponsor: Keymed Biosciences Co.Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 3 trial compares a new drug called CM336 against standard treatments for people with relapsed or refractory multiple myeloma who have already tried at least two prior therapies. About 280 participants will be randomly assigned to receive either CM336 or a standard-of-care regimen chosen by their doctor. The main goal is to see if CM336 can delay cancer progression better than current options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CM336
What this could lead to: If successful, CM336 could offer a new treatment option for people with multiple myeloma that has returned or not responded to prior therapies.
What could go wrong: This is an early-stage Phase 3 trial, so results are not guaranteed. The drug may not work better than current treatments, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA (MM)

Contacts and locations

Locations

Institute of Hematology & Blood Diseases Hospital

Tianjin, Tianjin Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.